The world’s biggest drugmaker, Pfizer, is set to bulk up its collaborative research partnerships with CROs and academics in Asia to lower costs and produce more affordable drugs.
Living Image Multi-Modality Software Module and Mouse Imaging shuttle will widen the understanding of animal biology in preclinical research, say Caliper Life Sciences.
Outsourcing-pharma takes a look at all the latest developments in the rapidly expanding drug development imaging sector with news from Aspect and Medisco, VirtualScopics and ABX-CRO and ACR Image Metrix.
The life sciences company, ForteBio, has launched its Dip and Read Protein G biosensor, designed for the fast-track analysis of specific biomolecular interactions of various types of the antibody molecule, mammalian immunoglobulin.
ADME/toxicity testing firm Cyprotexservice providers is bringing researchers free online access to its database of ADME and pharmacokinetic properties of marketed drugs, through Cloe Knowledge.
Aspect Magnetic Technologies claim its new compact M2 magnetic resonance imaging (MRI) systems “help preclinical researchers expand the horizons for completely new ideas and discovery.”
Biomarkers are critical to discovery and can help pharmaceutical firms make development a more efficient and cost effective process accord to bioanalysis services provider KCAS.
Cyprotex launches in vitro toxicology service, Cyprotox, after extending laboratory space at its Macclesfield, UK facility by 90 sq m. This gives the UK site the same in vitro capabilities as those of Apredica, US, which Cyprotex acquired in August.
Bioanalytical Systems, Inc (BASi) posted an operating profit in the third quarter, overturning a loss 12 months ago, as lower expenses offset a slight dip in revenue.
Charles River Laboratories (CRL) has abandoned plans to buy Wuxi Pharmatech after the $1.6bn (€1.2bn) takeover failed to gain sufficient shareholder support.
Demand for drug discovery services is growing again according to Domainex, who predicted that we will see greater pharmaceutical industry reliance on specialist CROs going forward.
Preclinical CRO Lab Research says new contracts are a sign of continuing recovery in market as well as firm’s ability to attract broader clientele base.
Major Charles River Laboratories (CRL) shareholder Jana Partners says Wuxi PharmaTech deal would generate inadequate returns, citing “industry” concerns about integration.
CRL has said the WuXi buy could add up to $100m (€78m) in additional annual revenue and spoken of clients’ enthusiasm for the deal as its attempts to shore up investor support.
reMYND NV is to offer the A4 amyloid testing service to support preclinical screening of Alzheimer’s treatments after inking a deal with Amorfix Life Sciences.
InhibOx and the Cambridge Crystallographic Data Centre (CCDC) say new drug discovery services partnership is motivated by market need for CADD expertise.
Contract services firm Albany Molecular Research (AMRI) hopes discovery deal with Aquapharm Biodiscovery will make a big splash in anti-microbials and anti-inflammatories.
Investors are funding the creation of a RUB1.6bn ($52m), 10,000 sq m preclinical Russian CRO to fill the gap in the nation’s development chain and undercut western prices by 40 per cent.
CeeTox has acquired laboratory assets and hired staff from ADMETRx, which has ceased operations, as part of its strategy of establishing itself as an in vitro services leader.
Covance has established a Discovery and Translational Services unit, integrating a number of existing operations, to foster greater scientific and technical collaboration.
French CRO Porsolt and UK counterpart KWS BioTest have teamed up to offer preclinical immunology and inflammation analysis services under a strategic alliance announced yesterday.
BioFocus is expanding its Huntingdon’s disease collaboration with CHDI by committing to take targets it developed in its earlier deal, through discovery as part of a five year, $41m (€31m) agreement.
Freeslate has entered into a strategic partnership with Johnson and Johnson (J&J) to provide the pharma with integrated workflows, software and research services until 2012.
Charles River Laboratories (CRL) has admitted that areas of overlap created by the WuXi acquisition will lead to a “refinement of certain operating units” but is yet to disclose details.
Charles River Laboratories (CRL) is to acquire WuXi PharmaTech for $1.6bn (€1.2bn), creating a global CRO capable of offering fully integrated services from molecule creation to first-in-human testing.
Charles River Laboratories’ (CRL) Shanghai preclinical test facility GLP certified by Belgian authorities under the OECD’s mutual acceptance of data framework.
DiscoveRx has added GPCR platforms to its portfolio, enhancing its ability to provide information on a compound’s mode of action, activated receptor recycling and efficacy in animal models.
Contract research organisation (CRO) Ricerca Biosciences has entered into a business development deal with Japan-based Life Science Partner (LSP) to help penetrate the Asian market.
France-based CRO Cellvax has moved to a new laboratory to provide clients with large animal services and new technical platforms, such as scintigraphy, histological analysis and biomarkers.
AniClin Preclinical Services has formed a strategic alliance with Taylor Technology, a subsidiary of PharmaNet, to offer clients complete pharmacokinetic (PK) studies in fewer than five days.
